Is Niagen Bioscience, Inc. (NAGE) Halal?

NASDAQ Healthcare United States $336M
✓ HALAL
Confidence: 95/100
Niagen Bioscience, Inc. (NAGE) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.7% against the AAOIFI threshold of 30%, Niagen Bioscience, Inc. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.7%
/ 30%
11.0%
/ 30%
1.9%
/ 30%
1.13%
/ 5%
✓ HALAL
DJIM 0.7%
/ 33%
11.0%
/ 33%
1.9%
/ 33%
1.13%
/ 5%
✓ HALAL
MSCI 3.9%
/ 33%
65.2%
/ 33%
11.4%
/ 33%
1.13%
/ 5%
✗ NOT HALAL
S&P 0.7%
/ 33%
11.0%
/ 33%
1.9%
/ 33%
1.13%
/ 5%
✓ HALAL
FTSE 3.9%
/ 33%
65.2%
/ 33%
11.4%
/ 50%
1.13%
/ 5%
✗ NOT HALAL

Financial Highlights

P/E Ratio
21.0
Forward: 12.2
EPS
$0.20
P/B Ratio
4.4
EV/EBITDA
18.2
EV: $275M
Revenue
$129M
Growth: 16.2%
Beta
2.2
High volatility
Current Ratio
4.9

Profitability

Gross Margin 64.3%
Operating Margin 6.2%
Net Margin 13.4%
Return on Equity (ROE) 28.3%
Return on Assets (ROA) 10.2%

Cash Flow & Balance Sheet

Operating Cash Flow$14M
Free Cash Flow$13M
Total Debt$3M
Debt-to-Equity3.7
Current Ratio4.9
Total Assets$106M

Price & Trading

Last Close$4.47
50-Day MA$5.25
200-Day MA$7.96
Avg Volume1.2M
Beta2.2
52-Week Range
$4.20
$14.69

About Niagen Bioscience, Inc. (NAGE)

CEO
Mr. Robert N. Fried
Employees
117
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$336M
Currency
USD

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Purification Calculator

As a halal stock with 1.13% impermissible income, you need to purify your dividends.

Enter your dividends to calculate purification amount

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Niagen Bioscience, Inc. (NAGE) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Niagen Bioscience, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Niagen Bioscience, Inc.'s debt ratio?

Niagen Bioscience, Inc.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.9%.

Does Niagen Bioscience, Inc. require dividend purification?

Yes, Niagen Bioscience, Inc. has an impermissible income ratio of 1.13%, which means 1.13% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.

What are Niagen Bioscience, Inc.'s key financial metrics?

Niagen Bioscience, Inc. has a market capitalization of $336M, trailing P/E ratio of 21.0, and revenue of $129M. The company maintains a gross margin of 64.3% and a net margin of 13.4%. Return on equity stands at 28.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.